Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data
CONCLUSION: This anchored ITC demonstrated a greater PFS benefit for D-Rd versus VRd in TIE patients with NDMM. In the absence of head-to-head trials comparing D-Rd and VRd, the present trial may help inform treatment selection in this patient population.PMID:38494542 | DOI:10.1007/s12325-024-02807-y
Source: Adv Data - Category: Epidemiology Authors: Brian G M Durie Shaji K Kumar Eric M Ammann Alex Z Fu Shuchita Kaila Annette Lam Saad Z Usmani Thierry Facon Source Type: research
More News: Dexamethasone | Epidemiology | Myeloma | Revlimid | Stem Cell Therapy | Stem Cells | Study | Transplants | Velcade